{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:11Z","timestamp":1790310071494,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T00:00:00Z","timestamp":1404864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0101591","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T19:33:20Z","timestamp":1404934400000},"page":"e101591","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":69,"title":["Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01151319","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Emma-Jo","family":"Hayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Ibrahimsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Del Sorbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony P.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"S Letourneau","year":"2007","journal-title":"PLoS ONE"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1097\/00002030-200312050-00005","article-title":"Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection","volume":"17","author":"M Altfeld","year":"2003","journal-title":"AIDS"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.immuni.2012.11.022","article-title":"Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen Design","volume":"38","author":"AL Ferguson","year":"2013","journal-title":"Immunity"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1084\/jem.193.3.375","article-title":"Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses","volume":"193","author":"AD Kelleher","year":"2001","journal-title":"J Exp Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm992","article-title":"HIV evolution: CTL escape mutation and reversion after transmission","volume":"10","author":"AJ Leslie","year":"2004","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"S Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/eji.201040344","article-title":"Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques","volume":"40","author":"M Rosario","year":"2010","journal-title":"Eur J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1128\/JVI.06535-11","article-title":"Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to conventional plasmid DNA vaccine","volume":"86","author":"ML Knudsen","year":"2012","journal-title":"J Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/QAD.0b013e32834ed9b2","article-title":"Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques","volume":"26","author":"M Rosario","year":"2012","journal-title":"AIDS"},{"key":"ref10","first-page":"5594","article-title":"Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB\/c mice Vaccine","volume":"31","author":"B Ondondo","year":"2013"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"N Borthwick","year":"2014","journal-title":"Mol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/501459","article-title":"Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya","volume":"42","author":"P Bejon","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.vaccine.2005.08.041","article-title":"Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers","volume":"24","author":"I Cebere","year":"2006","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e13983","DOI":"10.1371\/journal.pone.0013983","article-title":"Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate","volume":"5","author":"JR Currier","year":"2010","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.vaccine.2007.01.005","article-title":"Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag\/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy","volume":"25","author":"L Dorrell","year":"2007","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/509259","article-title":"Phase I Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate DNA Vaccine","volume":"194","author":"B Graham","year":"2006","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.vaccine.2008.02.071","article-title":"Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa","volume":"26","author":"W Jaoko","year":"2008","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2008.02.072","article-title":"EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone","volume":"26","author":"S McCormack","year":"2008","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"GA O'Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"SH Sheehy","year":"2012","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"SH Sheehy","year":"2013","journal-title":"Mol Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"SH Sheehy","year":"2012","journal-title":"Mol Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults","volume":"8","author":"C Ogwang","year":"2013","journal-title":"PLoS ONE"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"M Aste-Amezaga","year":"2004","journal-title":"Hum Gene Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Paris R, Kuschner RA, Binn L, Thomas SJ, Colloca S, <etal>et al<\/etal>.. (2014) Adenovirus type 4 and type 7 vaccination or type 4 respiratory infection elicit minimal cross-reactive antibody to non-human adenovirus vaccine vectors. Clin Vaccine Immunol.","DOI":"10.1128\/CVI.00011-14"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/14712598.2014.885946","article-title":"Conserved immunogens in prime-bost strategies for te next-generation HIV-1 vaccines","volume":"14","author":"T Hanke","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.0105-2896.2004.00151.x","article-title":"DNA vaccines against human immunodeficiency virus type 1","volume":"199","author":"MJ Estcourt","year":"2004","journal-title":"Immunol Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.vaccine.2005.08.048","article-title":"Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis","volume":"24","author":"SC Gilbert","year":"2006","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1586\/14760584.3.4.S89","article-title":"MVA as a vector for vaccines against HIV-1","volume":"3","author":"E-J Im","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e55831","DOI":"10.1371\/journal.pone.0055831","article-title":"Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers","volume":"8","author":"S Mehendale","year":"2013","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1089\/aid.2009.0096","article-title":"A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers","volume":"25","author":"VD Ramanathan","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"G Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"key":"ref34","unstructured":"Gilbert P, Follmann D (2013) Presentation of meta-analysis. Mini-Summit on Adenovirus Platforms for HIV Vaccines. Bethesda, Maryland, U.S.A. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.totalwebcasting.com\/view\/?id=niaid\" xlink:type=\"simple\">http:\/\/www.totalwebcasting.com\/view\/?id=niaid<\/ext-link>."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/infdis\/jis738","article-title":"Reply to Richie and Villasante","volume":"207","author":"A Duerr","year":"2013","journal-title":"J Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/505979","article-title":"HIV vaccines: new frontiers in vaccine development","volume":"43","author":"A Duerr","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, <etal>et al<\/etal>.. (2014) Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study. Lancet Infect Dis.","DOI":"10.1016\/S1473-3099(14)70020-9"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/infdis\/jis737","article-title":"Use of adenovirus serotype 5 vaccine vectors in seropositive, uncircumcised men: safety lessons from the step trial","volume":"207","author":"TL Richie","year":"2013","journal-title":"J Infect Dis"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, <etal>et al<\/etal>.. (2013) Efficacy Trial of a DNA\/rAd5 HIV-1 Preventive Vaccine. N Engl J Med.","DOI":"10.1056\/NEJMoa1310566"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"M Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"NA Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"N Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e41936","DOI":"10.1371\/journal.pone.0041936","article-title":"A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"MC Keefer","year":"2012","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0101591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T17:51:43Z","timestamp":1589046703000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0101591"}},"subtitle":[],"editor":[{"given":"Paul A.","family":"Goepfert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0101591","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]}}}